Tumor treating fields in combination with gemcitabine or gemcitabine plus nab-paclitaxel in pancreatic cancer: Results of the PANOVA phase 2 study

Tumor Treating Fields (TTFields), low intensity alternating electric fields with antimitotic activity, have demonstrated survival benefit in patients with glioblastoma. This phase 2 PANOVA study was conducted to examine the combination of TTFields plus chemotherapy in patients with pancreatic ductal...

Full description

Saved in:

Bibliographic Details
Published in:	Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] Vol. 19; no. 1; pp. 64 - 72
Main Authors:	Rivera, Fernando, Benavides, Manuel, Gallego, Javier, Guillen-Ponce, Carmen, Lopez-Martin, José, Küng, Marc
Format:	Journal Article
Language:	English
Published:	Switzerland Elsevier B.V 01.01.2019 Elsevier Limited
Subjects:	Adenocarcinoma Aged Aged, 80 and over Albumins - administration & dosage Albumins - therapeutic use Antineoplastic Agents - administration & dosage Antineoplastic Agents - therapeutic use Cancer therapies Cell adhesion & migration Chemotherapy Combined Modality Therapy Deoxycytidine - administration & dosage Deoxycytidine - analogs & derivatives Deoxycytidine - therapeutic use Electric fields Electric Stimulation Therapy Female Gemcitabine Glioblastoma Humans Male Medical equipment Metastases Metastasis Middle Aged Nab-paclitaxel Neutropenia Paclitaxel Paclitaxel - administration & dosage Paclitaxel - therapeutic use Pancreatic cancer Pancreatic Neoplasms Pancreatic Neoplasms - therapy PANOVA Patients Skin Survival Toxicity Tumor treating fields Israel PANOVA Tumor treating fields Gemcitabine Pancreatic cancer Nab-paclitaxel
ISSN:	1424-3903, 1424-3911, 1424-3911
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!